Franklin Genomic Advancements ETF
HELXBATSFranklin TempletonEquity
As of Oct 16, 2026 close
- Assets (AUM)
- $32.89M
- Expense ratio
- 0.50%
- Dividend yield
- 0.34%
- Holdings
- 72
- 52-week range
- $31.24$45.58
- Volume (live)
- -
- Avg. volume (3M)
- 10.29K
HELX ETF: Franklin Genomic Advancements ETF - Price, Holdings & Analysis
Franklin Genomic Advancements ETF Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fund characteristics, expense ratio, dividend yield, and performance metrics
| Day's Range | $41.21 - $41.28 |
|---|---|
| 52-Week High | $45.58 |
| 52-Week Low | $31.24 |
| Open | $41.28 |
| Volume (last close) | 2.07K |
| Average Volume (3M) | 10.29K |
| 1 Day Change | +1.53% |
|---|---|
| 1 Month Change | −1.31% |
| 6 Month Change | +22.26% |
| YTD Change | +16.75% |
| 1 Year Change | +28.52% |
| 5 Year Change | −15.52% |
| Annual Dividend | $0.14 |
|---|---|
| Dividend Yield | 0.34% |
| Last Dividend Ex-Date | Dec 30, 2025 |
| Assets (AUM) | $32.89M |
|---|---|
| Expense Ratio | 0.50% |
| Total Holdings | 72 |
| Inception Date | Feb 24, 2020 |
| 50-Day MA | $42.39 |
|---|---|
| 200-Day MA | $37.29 |
| RSI | 45.03 |
| Stochastic %K | 10.80 |
| Stochastic %D | 9.02 |
Source: Exchange price data and fund disclosures. Data as of Oct 16, 2026. Data sources and methodology
HELX at a Glance
Franklin Genomic Advancements ETF (HELX) is an equity ETF from Franklin Templeton, launched in February 2020. It manages $32.89M in assets and charges a 0.50% expense ratio, about $50 a year per $10,000 invested.
As of its Oct 4, 2026 holdings, it holds 72 positions. The largest are Natera, Inc. (NTRA, 10.26%), Guardant Health, Inc (GH, 10.14%) and Krystal Biotech, Inc (KRYS, 5.46%). The top 10 holdings make up 51.8% of the fund. By sector it leans toward Healthcare (96.9%), Materials (2.4%) and Technology (0.7%). 91.3% of assets are in the United States.
It pays distributions yielding 0.34% at the Oct 16, 2026 close, $0.14 per share over the trailing 12 months. As of the Oct 16, 2026 close, the share price is up 28.5% over one year and down 15.5% over five years (price change, excluding distributions).
Frequently Asked Questions About Franklin Genomic Advancements ETF
What is the current price of HELX?
The latest HELX price is $41.23 (Oct 16, 2026 close). The 52-week range is $31.24–$45.58. The share price is up 28.5% over the past year (price change, excluding distributions).
What is the expense ratio for HELX?
HELX's annual expense ratio is 0.50%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.
Does HELX pay dividends?
Yes, HELX pays a 0.34% dividend yield (trailing 12 months, at the Oct 16, 2026 close). The most recent ex-dividend date was December 30, 2025. View full dividend history in the Dividends section.
What are the top holdings of HELX?
As of Oct 4, 2026, HELX's largest holdings are Natera, Inc. (10.3%), Guardant Health, Inc (10.1%), Krystal Biotech, Inc (5.5%) (combined weight: 25.9%). The fund holds 72 total positions. View the complete portfolio breakdown in the Holdings section.
How does HELX compare to similar ETFs?
Compare HELX (0.50% expense ratio, $33M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.